#210 Blazing Through the Evidence on THC Versus CBD Combinations in Medical Cannabinoids.
CLINICAL QUESTION
Do tetrahydrocannabinol (THC), cannabidiol (CBD), or the THC/CBD combination yield differing benefits or harms?
BOTTOM LINE
From four randomized controlled trials (RCT), one found THC/CBD superior to THC but this was inconsistent within study and with other studies. Adverse events are prevalent in THC/CBD and individual components. While some early poor-quality research in healthy users suggest CBD may attenuate some psychiatric effects of THC, better research in real patients is needed to verify any benefits of specific components.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
Identified four RCTs comparing THC, CBD, or combined.
- RCT: 243 terminal cancer and weight loss patients, comparing THC/CBD versus THC versus placebo over six weeks.1
- THC/CBD versus THC: No statistical difference in appetite or adverse events.
- RCT: 177 refractory cancer pain patients on strong opioids (~270 mg morphine), comparing THC/CBD versus THC versus placebo over two weeks.2
- ≥30% pain reduction: 38% THC/CBD versus 21% THC, Number Needed to Treat=6.
- No difference for ≥10% or ≥50% pain reduction.
- Adverse events: No difference with THC/CBD versus THC.
- ≥30% pain reduction: 38% THC/CBD versus 21% THC, Number Needed to Treat=6.
- RCT: 48 brachial nerve injury patients, comparing THC/CBD versus THC versus placebo over two weeks.3
- Baseline pain 7.5/10: Both THC/CBD and THC groups reduced pain ~1.3 points, statistically significantly more than 0.6 with placebo.
- Adverse events not significantly different between THC/CBD and THC.
- ‘N of 1’ RCT: 24 chronic pain patients who benefitted from THC/CBD, compared THC/CBD versus THC versus CBD versus placebo over eight weeks.4
- Patients reporting equal/better pain management versus original THC/CBD.
- 38% THC/CBD, 33% THC, 17% CBD: Not statistically different.
- Patients reporting equal/better pain management versus original THC/CBD.
- RCT 120 Dravet syndrome pediatric patients: CBD reduced seizure frequency ~22% over placebo at 14 weeks.5
- Adverse events include somnolence (Number Needed to Harm (NNH)=4), diarrhea (NNH=5), and appetite loss (NNH=5).
- Recent RCT of lennox-gastaut (seizure) syndrome adults found similar.6
- Canadian guideline recommends cannabinoids only in refractory neuropathic pain, palliative cancer pain, chemotherapy-associated nausea/vomiting, and spasticity.7
- One guideline recommends low THC or high CBD:THC ratios to diminish THC adverse events.8
- Largely based on small studies of healthy volunteers (some with other drug use history) examining MRI or short-term scale changes.
Latest Tools for Practice
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)
What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
